Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx ...
COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. The GOLD system previously classified ...
Using 21 st century diagnostics to overcome barriers for lung function testing in primary care: it is time to consider oscillometry Obstructive airways diseases, including asthma and COPD as the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback